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We  have  evaluated  the capacity  of  an  oral multivalent  enterotoxigenic  Escherichia  coli  (ETEC)  vaccine
(MEV)  to induce  mucosal  immunological  memory.  MEV  consists  of four inactivated  E. coli  strains  over-
expressing  the  major  colonization  factors  (CFs)  CFA/I, CS3,  CS5  and  CS6  and  the  LTB-related  toxoid
LCTBA.  Memory  responses  were  analyzed  by comparing  the  magnitudes  and  kinetics  of intestine-derived
antibody-secreting  cell  responses  to  a single  dose  of  MEV  in three  groups  of  adult Swedish  volunteers
(n  =  16–19  subjects  per  group)  in a  Phase  I  trial:  non-immunized  controls  (I)  and  subjects  who  in a  pre-
vious  Phase  I trial 13–23  months  earlier  had  received  two biweekly  doses  of  MEV  (II)  or MEV  +  double
mutant  LT  (dmLT)  adjuvant  (III). Responses  against  CFs  and  LTB  were  analyzed  in antibodies  in  lym-
phocyte  secretions  (ALS)  of  blood  mononuclear  cells  collected  before  (day  0)  and  4/5  and  7  days  after
immunization.  Speciﬁc  circulating  memory  B  cells  present  at the  time  of the single  dose  vaccination  were
also  studied  to determine  if such  cells  may  reﬂect  mucosal  memory.
Considerably  higher  and signiﬁcantly  more  frequent  IgA  ALS  responses  against  all  CFs  and  LTB  were
induced  by the  single  vaccine  dose  in  the  previously  immunized  than  in  non-immunized  volunteers.
Furthermore,  peak  IgA  ALS  responses  against  all antigens  were  observed  on  days  4/5  in most  of the
previously  immunized  subjects  whereas  only  a few previously  non-vaccinated  individuals  responded
before  day  7.  Priming  with  adjuvant  did  not  inﬂuence  memory  responses.  Circulating  vaccine  speciﬁc  IgA
memory B cells  were  not  detected,  whereas  anti-toxin  IgG  memory  B cells  were  identiﬁed  13–23 months
after  priming  vaccination.We  conclude  that  MEV  induces  functional  mucosal  immunological  memory  which  remains  at least  1–2
years.  Furthermore,  our  results  support  that analysis  of  antibody-secreting  cell responses  after  booster
vaccination  may  be a useful  approach  to  evaluate  longstanding  mucosal  immunological  memory  in
humans.
Clinical  trials registration:  ISRCTN27096290.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-NDAbbreviations: AE, adverse event; ALS, antibodies in lymphocyte super-
atants/secretions; ASC, antibody-secreting cell; BAFF, B cell activating factor; CF,
olonization factor; CT, cholera toxin; CTB, cholera toxin binding subunit; dmLT,
ouble mutant LT; ETEC, enterotoxigenic Escherichia coli; GM,  geometric mean; LT,
eat labile toxin; LTB, heat labile toxin binding subunit; LCTBA, CTB/LTB hybrid pro-
ein; LPS, lipopolysaccharide; MEV, multivalent ETEC vaccine; PBMCs, peripheral
lood mononuclear cells; PPS, per protocol analysis set; PWM,  pokeweed mitogen;
AC,  Staphylococcus aureus protein A; SAS, safety analysis set; SIgA, secretory IgA;
T,  heat stable toxin.
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1. Introduction
Intense efforts are in progress to develop an effective vaccine
against the most common bacterial cause of diarrhea, i.e. entero-
toxigenic Escherichia coli (ETEC), in children in developing countries
and in travelers to these areas [1,2]. ETEC colonize the intesti-
nal mucosa by different speciﬁc colonization factors (CFs) on the
bacterial surface. Following colonization, the bacteria produce a
heat-labile toxin (LT) and/or a heat stable toxin (ST) that cause
watery diarrhea. An effective vaccine, particularly for use in ETEC
endemic countries, should not only induce acute, effective mucosal
IgA antibody responses against the most prevalent types of ETEC,
but also give rise to long-lasting immunological memory that can
be boosted by single vaccine doses given several years after ini-
tial vaccination. However, in most clinical vaccine studies, immune
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esponses are only assessed shortly after immunization. Studies of
ong term immunological memory to ETEC and other enteric vac-
ines have also been limited by the lack of suitable methods for
nalysis of mucosal memory responses in humans. Recent stud-
es suggest that mucosal infection and vaccination may  induce IgA
emory B cells that can be detected in peripheral blood [3–5], but
he duration of these memory B cell responses appear to be short in
he circulation, and the relation to functional mucosal memory has
ot been investigated. Hence, it is important to identify approaches
o evaluate if oral enteric vaccines can induce long term mucosal
emory in humans.
We have recently tested the safety and immunogenicity of a
ovel oral inactivated multivalent ETEC vaccine (MEV; trade name
TVAX) in a large Phase I trial in adult Swedish volunteers [6]. MEV
onsists of four inactivated E. coli strains over-expressing the most
ommon CFs, i.e. CFA/I, CS3, CS5 and CS6, and an LT binding sub-
nit (LTB) related toxoid; LCTBA [7]. Two doses of the vaccine were
hown to be safe, well tolerated and capable of inducing strong
ucosal immune responses against the key vaccine antigens, i.e.
he CFs and LTB, in a majority of vaccineess, as determined by anal-
sis of intestine-derived antibody-secreting cell (ASC) responses
s well as detection of antibodies in fecal extracts, when evaluated
–6 weeks after initial immunization [6]. Addition of a promising
ucosal adjuvant, double-mutant LT (dmLT) [8], in a dose of 10 g
nhanced immune response against the CFs present in the lowest
mounts in the vaccine [6], supporting the dose-sparing effect of
he adjuvant previously observed in animal studies [7].
Encouraged by these results we have now studied whether
he previous vaccinations with MEV  had induced an immuno-
ogical memory that could be boosted by a single vaccine dose
iven one to two years after the initial vaccination and whether
riming with dmLT inﬂuenced memory responses. We  have pre-
iously shown that adult Swedish volunteers primed with two
ral doses of an inactivated cholera vaccine (Dukoral®) responded
arlier than naïve subjects with peak intestine-derived circulat-
ng IgA ASC responses to a single oral booster dose given several
ears later [9]. Studies show that vaccine-speciﬁc ASC responses
n peripheral blood reﬂect intestinal ASC responses [10] as well as
ntibody responses in fecal or lavage specimens [11] after oral ETEC
r cholera vaccination, supporting the use of ASC assessment as a
urrogate for mucosal IgA responses. We  have now compared the
inetics and magnitudes of ASC as well as serum antibody responses
o a single dose of MEV  in subjects who 13–23 months earlier had
eceived two oral doses of MEV  alone or together with 10 g of
mLT and in previously non-immunized controls. ASC responses
ere analyzed by the antibodies in lymphocyte supernatants (ALS)
ssay, which we and others have shown give comparable results as
he more traditional ELISPOT assay for assessment of ASC responses
o ETEC and cholera vaccines [6,9,12,13]. We  also studied whether
he previous priming immunizations with MEV  had induced vac-
ine speciﬁc IgA and IgG memory B cells that were detectable in the
irculation at the time for the booster vaccination. Furthermore, we
nalyzed whether presence of circulating vaccine speciﬁc memory
 cells might predict functional immunological memory responses
licited by oral booster vaccination.
. Materials and methods
For additional information, see supplementary material.
.1. Study designThis was a three-armed, non-randomized, open-label, single-
enter Phase I trial. Random subsets of subjects who  had previously,
n a randomized, placebo controlled Phase I trial [6], received two4 (2016) 3132–3140 3133
oral doses two weeks apart with vaccine buffer alone (previous
Group A, now designated Group I; n = 13 of 34), MEV  alone (previ-
ous Group B, now Group II; n = 17 of 35) or MEV plus 10 g dmLT
(previous Group C, now Group III; n = 18 of 30) were enrolled. In
addition, 9 naïve controls, who  had not previously participated in
any ETEC vaccine trial, were recruited to the new Group I (total
n = 22). All subjects received one oral dose of MEV  alone (no adju-
vant) in 150 ml  bicarbonate buffer.
The study was  performed in accordance with the Declaration
of Helsinki and written informed consent was obtained from all
volunteers.
2.2. Immunological assays
Blood samples for isolation of peripheral blood mononuclear
cells (PBMCs) and serum were collected on the day of vaccina-
tion (day 0) and 4 or 5 and 7 days post vaccination. Mucosal
immune responses were evaluated by measuring intestine-derived
ASC responses in blood by the ALS assay and systemic immune
responses by determining serum antibody levels by ELISA [6,13].
Vaccine speciﬁc memory B cells in blood were determined by
stimulating PBMCs for 5–6 days with CpG DNA, pokeweed mitogen
(PWM)  and Staphylococcus aureus protein A (SAC), as described by
Crotty et al. [14], or with CpG DNA, IL-15 and B cell activating factor
(BAFF), as described by Tengvall et al. [15]. Numbers of speciﬁc ASCs
were determined by ELISPOT using plates coated with CFA/I, CS3,
CS5, CS6 or GM1  plus LTB [13,15,16].
2.3. Safety assessment
Safety was  determined by evaluation of adverse events (AEs) via
diary cards, physical examination, clinical chemistry and hemato-
logy tests.
2.4. Statistical analyses
Statistical differences were evaluated using paired and unpaired
t-tests and Fisher’s exact test. Correlations were evaluated by the
Pearson test. P-values < 0.05 were considered signiﬁcant.
3. Results
3.1. Study subjects
Of 64 subjects screened, 57 were enrolled and immunized,
resulting in 17–22 subjects in each of the three study groups (Fig. 1
and Table S1). In Groups II and III, the average time between the
initial (primary) [6] and the third (late booster) vaccination was
18 months (range 13–23 months, Table S1). For the ALS and serum
analyses, 52–54 subjects were included in the per protocol analysis
sets (PPS) and for the circulating memory B cell analyses 43 subjects
were included; reasons for exclusions are given in Figs. 1 and 6.
3.2. Safety
The vaccine was safe and well tolerated with similar low fre-
quencies of mainly mild AEs reported in all groups (Table S2). No
serious AEs (SAEs) or severe AEs were reported.
3.3. Immune responsesSubjects immunized with MEV  alone (Group II) or MEV  + 10 g
dmLT (Group III) 13–23 months earlier [6] were orally immu-
nized with a single dose of MEV; their intestine-derived vaccine
speciﬁc ALS responses in the circulation were compared with
3134 A. Lundgren et al. / Vaccine 34 (2016) 3132–3140
1 Two subjects (one male , one female) fro m Group I were exclude d fr om al l PP S use d fo r imm unological
analyse s du e to trave l to ET EC endemi c countries ≤3 years prio r to vaccinatio n (trave l history reveale d aft er
screening an d booste r vaccination).
2 A few samples coul d no t be evaluate d due to unspecifi c binding in EL ISA ass ays, resultin g in exclusio n of
one male subj ect fro m Group I fr om al l ALS and serum PPS an d one femal e subjec t from Group II an d one
female subject fro m Group II I fr om the CF ALS PP S.
22 enrolled  
and immunized
Enrollment
4 excluded;  
met excl.crit. 
26 screened  
for eligibility
Group I
18 screened 
for eligibilit y
Grou p II
18 enrolled 
and immunize d
20 screened 
for eligibilit y
Grou p II I
22 comple ted  
last visit
SAS: 22
PPS: 19  1, 2
17 comple ted  
last visit
SAS: 17
PPS: 16-17  2
18 completed 
last visit
SAS: 18
PPS: 17-18 2
1 eligible  but  
not randomized, 
selected 
as alternate
2 excluded;  
met excl.crit. 
Enrollment Enrollment
17 enrolled 
and immunized
Fig. 1. Trial proﬁle. All safety analyses were performed on the safety analysis set (SAS), including all subjects that received one dose of MEV  vaccination (all 57 enrolled
subjects). All immunogenicity analyses were performed on the per protocol sets (PPS), which were deﬁned per specimen (ALS, serum or circulating memory B cells) and
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s  deﬁned in Fig. 6.
orresponding responses induced by a single dose of MEV  in previ-
usly non-vaccinated subjects (Group I).
.3.1. Intestine-derived anti-CF ALS responses
A majority of subjects (53–88%) in Groups II and III responded to
he single booster vaccine dose with signiﬁcant ALS IgA responses
o all four vaccine CFs (CFA/I, CS3, CS5 and CS6; Fig. 2), with peak
esponses detected already on day 4/5 and lower responses on
ay 7 (signiﬁcant declines for all antigens except CS5). In con-
rast, only 11% of the non-vaccinated subjects in Group I developed
LS responses to CFA/I, CS5 or CS6, respectively, and 26% to CS3
fter single dose vaccination (Fig. 2). The responses detected on
ay 4/5 in Groups II and III were signiﬁcantly higher and/or more
requent than all anti-CF responses in Group I (Fig. 2). No differ-
nces in responses to any of the vaccine CFs were observed in
ubjects primed with MEV  alone and MEV  + dmLT (Group II versus
II; P > 0.05).
.3.2. Intestine-derived anti-LTB and anti-O78 LPS ALS responses
All subjects in Groups II and III responded with signiﬁcant
TB-speciﬁc IgA and IgG antibodies in ALS specimens after the
ooster vaccination; peak responses were detected on day 4/5 post
accination in a majority of subjects and the responses declined sig-
iﬁcantly until day 7 (Fig. 3A and B). In contrast, only 11–16% of the
ubjects in Group I responded to LTB; for those responding, highest
esponses were detected on day 7, the latest time point studied.
oth the frequencies and magnitudes of anti-LTB responses were
igniﬁcantly higher in the primed than in the non-primed subjects
Fig. 3A and B). Comparable anti-LTB ALS responses were observed
n subjects primed with MEV  alone and MEV  + 10 g dmLT (Group
I versus III; P > 0.05).
All subjects in Group II and III also responded to booster vaccina-
ion with anti-O78 lipopolysaccharide (LPS) IgA ALS responses that
eaked on day 4/5 and then signiﬁcantly declined (Fig. 3C). Sub-
ects in Group I also developed signiﬁcant anti-LPS IgA responses,
ut these responses were comparable on day 4/5 and day 7.in the standard operating procedure for each assay type were included in the PPS.
 reasons for exclusion are listed in the footnote. The circulating memory B cell PPS
Comparable ALS responses to CFs, LTB and O78 LPS were induced
when the booster vaccine dose was administered 13–18 months
(n = 19–20) compared to 19–23 months (n = 14–15) after primary
vaccination (not shown).
3.3.3. Comparison of ALS responses on day 4 and 5
To identify the optimal time point for assessing intestine-
derived immune responses after booster vaccination, ALS
responses to the different CFs, LTB and O78 LPS were com-
pared on day 4 and 5 in the previously vaccinated subjects. ALS
responses to CFA/I, CS5, CS6 and LTB were signiﬁcantly higher
and/or more frequent on day 5 than day 4 (Fig. 4A and B), whereas
responses against CS3 and O78 LPS did not differ signiﬁcantly
between the days (Fig. 4A and C).
3.3.4. Serum antibody responses
The systemic memory responses were analyzed by measuring
serum antibody responses to a single dose of MEV. Whereas anti-
LTB serum IgA titers were comparable in all three groups before
vaccination, anti-LTB IgG titers were signiﬁcantly higher in Group
II and III than Group I (P < 0.001). The majority (88–94%) of sub-
jects in Groups II and III developed signiﬁcant anti-LTB serum IgA
and IgG responses to the booster vaccination, whereas only 11%
of the Group I subjects responded with signiﬁcant anti-LTB titers
(Fig. 5A and B). Strongest responses to LTB were detected on day
7 in all groups and these responses were signiﬁcantly higher than
on day 4/5. Signiﬁcantly higher magnitudes as well as frequencies
of responses were detected both on day 4/5 and day 7 in Group
II and III compared to Group I subjects (Fig. 5A and B). No differ-
ences in magnitudes or frequencies of serum anti-LTB responses
were recorded between Group II and III.
Strongest anti-O78 LPS IgA serum responses were detected on
day 7 and these responses were comparable in the three study
group (Fig. 5C).
None of the subjects in Group I developed serum IgA antibody
responses to any of the CFs. The frequencies of IgA responders to
A. Lundgren et al. / Vaccine 34 (2016) 3132–3140 3135
Fig. 2. ALS responses to vaccine CFs after administration of a single oral dose of MEV. IgA ALS responses against CFA/I (A), CS3 (B), CS5 (C) and CS6 (D) were determined
in  previously non-vaccinated subjects (Group I) and in subjects previously immunized with two  oral doses of MEV alone (Group II) or two  doses of MEV plus 10 g dmLT
(Group  III). Geometric mean (GM + SEM) levels of antibodies in samples collected before (day 0) and 4/5 and 7 days after administration of a single dose of MEV are shown as
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Fs were also low in Groups II and III; 24% responded to CS3 and
bout 10% to the other CFs (not shown).
.3.5. Circulating vaccine speciﬁc memory B cells
We  also evaluated whether the primary vaccinations had
nduced circulating memory B cells that remained at the time for
he late booster vaccination. Circulating CF- and LTB-speciﬁc mem-
ry B cells were analyzed in blood samples collected before giving
he booster dose to Groups II and III, and for comparison also
efore vaccination of Group I. Memory B cells were transformed
nto cells actively secreting antibodies by polyclonal stimulation
ith CpG DNA, PWM  and SAC [14]. The frequencies of CF-speciﬁcgA and IgG memory B cells were low and comparable in all three
roups (not shown). However, we detected signiﬁcantly higher
TB-speciﬁc IgG secreting cells in Groups II and III compared to
n the non-vaccinated controls in Group I (Fig. 6A). The frequencieshe graphs. Responder frequencies (RF; %) on day 4 or 5 post vaccination are shown
 and III versus Group I, respectively, on day 4/5 are indicated. ns; not signiﬁcant.
of pre-existing LTB-speciﬁc IgG memory B cells before vaccination
correlated signiﬁcantly with the magnitudes of ALS IgG responses
induced by the booster vaccination (Fig. 6B). In contrast, no signiﬁ-
cant differences in LTB-speciﬁc IgA secreting cells were detected
between the previously vaccinated and non-vaccinated groups
(Fig. 6C). Similar results were obtained using an alternative sti-
mulatory cocktail [15] consisting of CpG DNA, IL-15 and BAFF (not
shown).
3.3.6. Comparison of responses after primary and booster
vaccinations
We compared IgA ALS responses induced by the initial two
oral doses of MEV  determined in the previous primary vaccination
study [6] with the responses induced by the single booster dose
in the same subset of subjects in the present study. The magni-
tudes of ALS responses 5 days after booster vaccination were at least
3136 A. Lundgren et al. / Vaccine 34 (2016) 3132–3140
Fig. 3. ALS responses to LTB and O78 LPS after administration of a single oral dose of MEV. IgA (A) and IgG (B) ALS responses against LTB and IgA responses against LPS (C)
were  determined in previously non-vaccinated subjects (Group I) and in subjects previously immunized with two oral doses of MEV  alone (Group II), or two doses of MEV
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EV  are shown as bars. Results of statistical comparisons between groups and tim
elow the graphs; results of statistical comparisons of responder frequencies in Gro
omparable, and for some antigens (CS3, LTB and O78 LPS) signiﬁ-
antly higher compared to the responses detected 5 days after the
econd vaccine dose in the previous study (Table S3). For additional
nformation about this comparison, see Supplementary material.
. Discussion
We  show that two oral doses of an oral inactivated whole cell
TEC vaccine, MEV  [6,7], is capable of inducing signiﬁcant func-
ional mucosal immunological IgA memory IgA to the primary
accine antigens, i.e. LTB and four different CFs. Thus, memory B
ells induced by the initial two dose vaccination could quickly be
eactivated by a single booster dose given 13–23 months later. This
as shown by the appearance of considerably higher, more fre-
uent and earlier appearing intestine-derived IgA ALS responses
n the circulation after administration of a single dose of MEV  in
he previously vaccinated than in previously non-vaccinated sub-
ects. Indeed, maximal ALS responses were detected already on
ay 5 in the primed individuals, whereas the highest responses collected before (day 0) and 4/5 and 7 days after administration of a single dose of
ts are indicated in the graphs. Responder frequencies (RF; %) on day 4/5 are shown
 and III versus Group I, respectively, on day 4/5 are indicated. ns; not signiﬁcant.
in previously non-vaccinated volunteers were detected on day 7
among the time points evaluated.
Our results are consistent with previous ﬁndings that speciﬁc
IgA memory responses against cholera toxin binding (CTB) subunit
could be induced locally in the intestine by the oral CTB-containing
cholera vaccine, Dukoral. Thus, presence of vaccine speciﬁc mem-
ory IgA cells in the intestinal mucosa, that could be reactivated by
administration of a single oral vaccine dose 5 months after pri-
mary vaccination, has been reported [10]. Furthermore, we have
detected rapid anamnestic responses in intestinal lavages already
3 days after a late booster vaccination given 15 months after pri-
mary vaccinations [17] and in ALS samples on day 4 or 5 after a late
booster given up to 14 years after priming [9]. Since CTB is highly
homologous to the LCTBA molecule in MEV  [18], it is likely that
mucosal memory responses to LTB, and potentially also to CFs and
LPS, may  be even more long-lived than shown in the present study.
ASC responses in blood induced by the oral typhoid vaccine Ty21a
also peak slightly earlier after booster compared to primary vac-
cine doses, administered 1–2 years previously, indicating persistent
A. Lundgren et al. / Vaccine 3
Fig. 4. Comparison of ALS responses on day 4 and 5 after booster vaccination. IgA
ALS responses to CFA/I, CS3, CS5 and CS6 (A), IgA and IgG ALS responses to LTB (B)
and  IgA ALS responses to O78 LPS (C) on day 4 (striped bars) and day 5 (black bars),
respectively, after administration of a single oral booster dose of MEV in subjects
previously immunized with two oral doses of MEV  alone or MEV plus 10 g dmLT
(Groups II and III combined). Magnitudes of responses (GM + SEM) are shown as
bars  and responder frequencies (RF; %) are indicated below the graphs. The results
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ay 4 versus day 5 are shown. ns; not signiﬁcant.
ucosal memory [19]. These results support that analysis of blood
SC/ALS responses may  be a simple approach to assess intestine-
erived memory responses after oral immunization in humans and
hat the method can be applied to different types of vaccines and
ntigens.
Almost 100% of speciﬁc ASCs which transiently migrate through
eripheral blood after oral cholera vaccination express the mucosal
oming marker 47 [20], supporting the mucosal origin and
estination of these cells. High expression of 47 on antibody
ecreting plasmablasts has also been observed after oral typhoid
nd Shigella vaccination [21,22]. Vaccine speciﬁc ASC responses in
he circulation have been shown to reﬂect intestinal ASC responses
10] as well as antibody responses in fecal or lavage specimens [11]
fter oral cholera and ETEC vaccinations. These ﬁndings strongly
upport that determination of vaccine-speciﬁc blood ASC responses
fter mucosal booster vaccination can be used to assess intestinal
mmune responses. However, the migration of speciﬁc ASCs from
he mucosa into peripheral blood after vaccination seems to be
ore transient than previously realized. Thus, ASC responses have4 (2016) 3132–3140 3137
been recommended to be optimally analyzed 6–8 days after oral
vaccination [23] and have usually been assessed 7–10 days after
each vaccine dose [24–30]. In the present study, however, we  found
that the optimal time point to analyze ALS responses in primed indi-
viduals was 5 days after the booster and that responses declined
markedly from day 5 to 7. This response kinetics differs from that
in the non-primed individuals in whom highest ALS responses were
detected on day 7. In a previous study of ALS responses to the
oral cholera vaccine Dukoral, responses remained high or even
increased slightly in a few subjects on day 9 compared to day 7
after the ﬁrst dose [9], supporting that ALS responses to a ﬁrst oral
vaccine dose are more prolonged than responses to later doses,
which we have observed to be very transient. These ﬁndings sug-
gest that ASC responses against CFs and toxin antigens to repeated
oral vaccine doses may  have been grossly underestimated in several
previous studies, which often have shown similar, or even lower,
responses to a second than a ﬁrst dose of cholera or ETEC vaccine
when measured 7 days after vaccination [13,16,24–28].
Previous studies of memory B cell responses in humans have
primarily been based on polyclonal stimulation and transforma-
tion of memory B cells into ASCs which can be detected using
ELISPOT. This method was  initially developed for analysis of mem-
ory B cell responses induced by parenteral vaccination [14], but has
more recently also been used to analyze circulating memory B cells
speciﬁc for ETEC, Shigella and cholera antigens after oral vaccina-
tion or natural infection [3–5,31–33]. In most studies memory B
cells have only been analyzed 1–3 months after mucosal vaccina-
tion or infection. E.g. in a recent study, ETEC infection was shown
to induce IgA and IgG memory B cells speciﬁc for LTB, CFA/I or
CS6 which could be detected in the circulation one month after
infection [5]. In a few studies of longer duration, CTB-speciﬁc IgG
memory B cells have been identiﬁed in the circulation 3–6 months
after oral cholera vaccination and 6–12 month after cholera infec-
tion, whereas IgA memory B cells only remained for one month
after vaccination and 3–9 months after infection [3,4,32]. In the
present study, we analyzed the occurrence of circulating vaccine
speciﬁc memory B cells 13–23 months after primary ETEC vaccina-
tion. Consistent with previous cholera vaccine studies, signiﬁcant
frequencies of vaccine speciﬁc circulating IgA memory B cells were
not detected at this late time point. Thus, although IgA memory B
cells may  remain for prolonged periods in intestinal mucosa and
can be rapidly reactivated upon challenge, such cells only circulate
for a few months after vaccination. In contrast, we  found signiﬁcant
frequencies of circulating LTB-speciﬁc IgG memory B cells up to
23 months post vaccination. These frequencies correlated with the
LTB-speciﬁc IgG ALS responses induced by the single booster dose
of MEV. Collectively, our results suggest that long-term mucosal
memory IgA responses, at variance with memory IgG responses,
cannot be assessed by analysis of circulating memory B cells.
One possibility to improve the immunogenicity of an oral whole
cell ETEC vaccine, particularly for use in children, who may require
reduced doses of vaccine to avoid gastro-intestinal side-effects
[1,34], is to administer the vaccine together with a mucosal adju-
vant. In the primary vaccination study, MEV  was given alone or
together with dmLT adjuvant [6]. Since the ALS responses to the
CFs present in the lowest amounts in MEV  were increased by co-
administration of the vaccine with dmLT in that study, we  evaluated
whether the adjuvant might have affected the development of
immunological memory. However, the strong memory responses
induced against all primary vaccine antigens in the previously vac-
cinated subjects, irrespective of whether they had been primed
with or without dmLT, does not support a beneﬁcial effect of the
adjuvant on memory development. Further studies will be under-
taken to evaluate the effect of dmLT on both primary and memory
B cell responses in young children and infants, who may  require
lower doses of vaccine.
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Fig. 5. Serum antibody responses to LTB and O78 LPS after administration of a single oral dose of MEV. IgA (A) and IgG (B) serum antibody responses against LTB and IgA
serum  antibody responses against LPS (C) in previously non-vaccinated subjects (Group I) and in subjects previously immunized with two oral doses of MEV  alone (Group II)
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f  a single dose of MEV  are shown as bars. Results of statistical comparisons betwe
ay  7 are shown below the graphs; results of statistical comparisons of responder f
Our study also suggests that MEV  induces memory responses
o O78 LPS. In contrast to the responses to the protein antigens,
trong anti-LPS ALS responses were detected already on day 4/5
lso in the previously non-vaccinated individuals. However, one of
he main distinguishing features of a recall response, i.e. a decline
n ALS antibody levels from day 4/5 to day 7, was also observed for
nti-O78 LPS responses in the previously vaccinated subjects. Given
hat O78 LPS is one of the most common types of LPS expressed by
TEC, and is also prevalent among other E. coli colonizing humans
35], the rapid LPS response in previously non-vaccinated subjects
ay  at least partly be explained by natural exposure to O78 E. coli.
We also demonstrated systemic memory responses to LTB,
ince signiﬁcantly higher and more frequent anti-LTB IgA and IgG
erum responses were detected in response to a single dose of
EV  in previously vaccinated compared to non-vaccinated sub-
ects. However, at variance with the ALS responses, higher and
ore frequent serum antibody responses were detected on day compared to day 4/5. In contrast, serum responses to O78 LPS
ere comparable in previously non-vaccinated and vaccinated sub-
ects. Serum responses to CFs were infrequent after both primary
nd booster vaccination. Thus, memory responses to CFs or LPStibodies in samples collected before (day 0) and 4/5 and 7 days after administration
ups and time points are indicated in the graphs. Responder frequencies (RF; %) on
ncies in Groups II and III versus Group I on day 7 are indicated. ns; not signiﬁcant.
could be detected using analysis of kinetics and magnitudes of ALS
responses, but not by analysis of serum antibodies.
Comparison of ALS responses to the initial two doses of MEV
and to a late booster revealed that the booster induced compa-
rable, or even higher, responses to the primary vaccine antigens.
However, responses to the late booster dose are unlikely to reﬂect
responses which may  be elicited by administration of a third dose
of MEV  shortly after the two  ﬁrst doses. Comparisons of intestinal
antibody responses to CFs and CTB in intestinal lavage specimens
after oral administration of two  and three doses of a previous oral
inactivated whole cell ETEC vaccine candidate demonstrated that
maximal responses were achieved already after the second dose
and were even lower after the third dose administered two weeks
later [36]. The strong responses observed to the late booster in the
present study may  suggest efﬁcient reactivation of long-lived high
afﬁnity memory B cells. Thus, a single booster dose of vaccine given
≥2 years after the initial priming may  be sufﬁcient to induce com-
parable, or even higher, levels of immune responses than induced
by the initial vaccinations.
In summary, our results show that the oral ETEC vaccine studied
induces memory IgA responses to all primary vaccine antigens in a
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Fig. 6. LTB-speciﬁc memory B cells in the circulation 13–23 months after primary MEV  vaccination. LTB-speciﬁc IgG (A and B) and IgA (C) memory B cells in non-vaccinated
subjects (Group I) and in subjects immunized with two  oral doses of MEV  alone (Group II) or MEV  plus 10 g dmLT (Group III) 13–23 months earlier, as detected by polyclonal
stimulation with CpG DNA, PWM  and SAC followed by ELISPOT analysis. Frequencies (%) of LTB speciﬁc IgG or IgA ASCs per total numbers of IgG (tIgG)or IgA (tIgA) secreting
ASCs  prior to vaccination (on day 0) in the present trial are indicated. (B) Correlations between frequencies of LTB-speciﬁc IgG circulating memory cells before vaccination and
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ajority of subjects and that these responses persist for at least 1–2
ears after vaccination. The results also suggest that a single vaccine
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